BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 17964232)

  • 1. PI3K/PTEN signaling in tumorigenesis and angiogenesis.
    Jiang BH; Liu LZ
    Biochim Biophys Acta; 2008 Jan; 1784(1):150-8. PubMed ID: 17964232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
    Fang J; Ding M; Yang L; Liu LZ; Jiang BH
    Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer.
    Dillon RL; White DE; Muller WJ
    Oncogene; 2007 Feb; 26(9):1338-45. PubMed ID: 17322919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K/PTEN signaling in angiogenesis and tumorigenesis.
    Jiang BH; Liu LZ
    Adv Cancer Res; 2009; 102():19-65. PubMed ID: 19595306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
    Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
    Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
    Carnero A; Blanco-Aparicio C; Renner O; Link W; Leal JF
    Curr Cancer Drug Targets; 2008 May; 8(3):187-98. PubMed ID: 18473732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells.
    Ma J; Sawai H; Ochi N; Matsuo Y; Xu D; Yasuda A; Takahashi H; Wakasugi T; Takeyama H
    Mol Cell Biochem; 2009 Nov; 331(1-2):161-71. PubMed ID: 19437103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting phosphoinositide 3-kinase: moving towards therapy.
    Marone R; Cmiljanovic V; Giese B; Wymann MP
    Biochim Biophys Acta; 2008 Jan; 1784(1):159-85. PubMed ID: 17997386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis.
    Joshi S; Singh AR; Zulcic M; Durden DL
    Mol Cancer Res; 2014 Oct; 12(10):1520-31. PubMed ID: 25103499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.
    Haddadi N; Lin Y; Travis G; Simpson AM; Nassif NT; McGowan EM
    Mol Cancer; 2018 Feb; 17(1):37. PubMed ID: 29455665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN, more than the AKT pathway.
    Blanco-Aparicio C; Renner O; Leal JF; Carnero A
    Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1α mediated by the PTEN/PI3K/Akt pathway.
    Park JH; Lee JY; Shin DH; Jang KS; Kim HJ; Kong G
    Oncogene; 2011 Nov; 30(45):4578-89. PubMed ID: 21602890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway.
    Wang F; Li L; Chen Z; Zhu M; Gu Y
    Int J Mol Med; 2016 May; 37(5):1421-8. PubMed ID: 26951965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).
    Hafsi S; Pezzino FM; Candido S; Ligresti G; Spandidos DA; Soua Z; McCubrey JA; Travali S; Libra M
    Int J Oncol; 2012 Mar; 40(3):639-44. PubMed ID: 22200790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKT signaling in regulating angiogenesis.
    Jiang BH; Liu LZ
    Curr Cancer Drug Targets; 2008 Feb; 8(1):19-26. PubMed ID: 18288940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
    Newton HB
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
    Nozhat Z; Hedayati M
    Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.